Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs

Charles J. Milrod, Frances Blevins, David Hughes, Adam Lerner, Shayna Sarosiek, Vaishali Sanchorawala, J. Mark Sloan

Blood (2021) 137 (21): 2987–2989.

https://doi.org/10.1182/blood.2021010853

Published: 2021

Includes: Supplemental data

Journal Articles

Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study

Vaishali Sanchorawala, Shayna Sarosiek, Amanda Schulman, Meredith Mistark, Mary Ellen Migre, Ramon Cruz, J. Mark Sloan, Dina Brauneis, Anthony C. Shelton

Blood (2020) 135 (18): 1541–1547.

https://doi.org/10.1182/blood.2019004436

Published: 2020

Journal Articles

Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation

Shayna Sarosiek, Karen Quillen, J. Mark Sloan, Dina Brauneis, Vaishali Sanchorawala

Blood (2018) 132 (7): 755–757.

https://doi.org/10.1182/blood-2018-03-838672

Published: 2018

Journal Articles

Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation

Sabrina Browning, Karen Quillen, J. Mark Sloan, Gheorghe Doros, Shayna Sarosiek, Vaishali Sanchorawala

Blood (2017) 130 (11): 1383–1386.

https://doi.org/10.1182/blood-2017-06-788729

Published: 2017

Journal Articles

Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial

Vaishali Sanchorawala, Anthony C. Shelton, Stephen Lo, Cindy Varga, J. Mark Sloan, David C. Seldin

Blood (2016) 128 (8): 1059–1062.

https://doi.org/10.1182/blood-2016-04-710822

Published: 2016

Journal Articles

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience

Vaishali Sanchorawala, Fangui Sun, Karen Quillen, J. Mark Sloan, John L. Berk, David C. Seldin

Blood (2015) 126 (20): 2345–2347.

https://doi.org/10.1182/blood-2015-08-662726

Published: 2015

Journal Articles

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center

Stephanie B. Tsai, David C. Seldin, Karen Quillen, John L. Berk, Frederick L. Ruberg, Hans Meier-Ewert, J. Mark Sloan, Gheorghe Doros, Kathleen T. Finn, Martha Skinner, Vaishali Sanchorawala

Blood (2012) 120 (22): 4445–4446.

https://doi.org/10.1182/blood-2012-09-457341

Published: 2012

Journal Articles

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

Maria Teresa Cibeira, Vaishali Sanchorawala, David C. Seldin, Karen Quillen, John L. Berk, Laura M. Dember, Adam Segal, Frederick Ruberg, Hans Meier-Ewert, Nancy T. Andrea, J. Mark Sloan, Kathleen T. Finn, Gheorghe Doros, Joan Blade, Martha Skinner

Blood (2011) 118 (16): 4346–4352.

https://doi.org/10.1182/blood-2011-01-330738

Published: 2011

Journal Articles

High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis

Vaishali Sanchorawala, MD, Karen Quillen, MD, MPH, Kathleen T Finn, ANP, Nancy T Andrea, MD, J. Mark Sloan, MD, Laura Dember, MD, Adam Segal, MD, Gheorghe Doros, PhD, Martha Skinner, MD, David Seldin, MD

Blood (2010) 116 (21): 3553.

https://doi.org/10.1182/blood.V116.21.3553.3553

Published: 2010

Journal Articles

Macroglossia – Not Always AL Amyloidosis

Andrew J Cowan, MD, Martha Skinner, MD, J. Mark Sloan, MD, John L Berk, MD, Carl J O'Hara, MD, David C Seldin, MD, PhD, Vaishali Sanchorawala, MD

Blood (2010) 116 (21): 5007.

https://doi.org/10.1182/blood.V116.21.5007.5007

Published: 2010

Journal Articles

Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients

M. Teresa Cibeira, MD, PhD, Vaishali Sanchorawala, MD, David C Seldin, MD, PhD, Karen Quillen, MD, MPH, Nancy Andrea, MD, J. Mark Sloan, MD, Kathleen T Finn, ANP, John L Berk, MD, Gheorghe Doros, PhD, Joan Blade, Martha Skinner, MD

Blood (2010) 116 (21): 2394.

https://doi.org/10.1182/blood.V116.21.2394.2394

Published: 2010

NARROW

Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs

Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study

Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation

Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation

Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis

Macroglossia – Not Always AL Amyloidosis

Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only